Is Bliss GVS Pharma overvalued or undervalued?

As of 27 June 2025, Bliss GVS Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 19.63, an EV to EBITDA of 12.07, and a Price to Book Value of 1.58. In comparison to its peers, Sun Pharma is considered expensive with a PE ratio of 35.42, while Dr. Reddy's Labs is attractive at a PE of 19.23, suggesting that Bliss GVS Pharma is positioned reasonably within its competitive landscape.
Despite a strong one-year stock return of 54.05% compared to the Sensex's 6.08%, the company's year-to-date performance shows a decline of 4.62%, which could indicate market corrections or profit-taking. Overall, while Bliss GVS Pharma is fairly valued, its performance metrics suggest it may have room for improvement to regain its previous attractive status.